Concessional Basic Customs Duty on Ethernet switches: classification as enterprise switches upheld, challenge dismissed for lack of substantial law qu...
Insolvency petition based on admitted debt and default upheld; challenge for malicious initiation rejected, settlement may proceed under resolution fr...
Quashing of FIR and challenge to ECIR over alleged diversion of funds and preferential ESOP pricing dismissed after prima facie money-laundering findi...
When a product falls within both a general tariff entry and a specific entry, the specific entry prevails; Active Pharmaceutical Ingredients (APIs) and bulk drugs satisfy the statutory definition of "drug" and are classifiable under the specific entry SI. No. 226 for tariff rate purposes rather than under general chemical headings. The statutory definition of drug is wide and expressly includes substances intended as components of drugs, and regulatory treatment and definitions across drug control rules confirm that APIs retain their character as drugs even when imported for testing, bioequivalence, bioavailability or clinical trials. Consequently, APIs/bulk drugs attract IGST as per SI. No. 226 except where a nil-rated entry applies.
When a product falls within both a general tariff entry and a specific entry, the specific entry prevails; Active Pharmaceutical Ingredients (APIs) and bulk drugs satisfy the statutory definition of "drug" and are classifiable under the specific entry SI. No. 226 for tariff rate purposes rather than under general chemical headings. The statutory definition of drug is wide and expressly includes substances intended as components of drugs, and regulatory treatment and definitions across drug control rules confirm that APIs retain their character as drugs even when imported for testing, bioequivalence, bioavailability or clinical trials. Consequently, APIs/bulk drugs attract IGST as per SI. No. 226 except where a nil-rated entry applies.
Note: It is a system-generated summary and is for quick reference only.